{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"33.7","value":"20.0"},{"groupId":"OG001","lowerLimit":"14.6","upperLimit":"40.3","value":"26.0"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"16.2","value":"5.9"},{"groupId":"OG003","lowerLimit":"7.8","upperLimit":"31.4","value":"17.4"}]}],"title":"Estrogen and/or Progesterone +ve (n=50,50,51,46)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.4","upperLimit":"50.7","value":"36.8"},{"groupId":"OG001","lowerLimit":"49.3","upperLimit":"75.6","value":"63.2"},{"groupId":"OG002","lowerLimit":"16.1","upperLimit":"41.0","value":"27.3"},{"groupId":"OG003","lowerLimit":"17.9","upperLimit":"44.6","value":"30.0"}]}],"title":"Estrogen and/or Progesterone -ve (n=57,57,55,50)"},{"categories":[{"measurements":[{"comment":"There were no participants in this category.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There were no participants in this category.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"comment":"There were no participants in this category.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Receptor Status Unknown (0,0,1,0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"96"}],"units":"Participants"}],"description":"pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg on Day 1 of Cycles 2-4 and docetaxel IV infusion at a starting dose of 75 mg/m\\^2 on Day 1 of Cycle 1 followed by 100 mg/m\\^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.\n\nAdjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 17.","id":"OG000","title":"Trastuzumab+Docetaxel"},{"description":"Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg and pertuzumab IV infusion at a loading dose of 840 mg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg trastuzumab and 420 mg pertuzumab on Day 1 of Cycles 2-4. Docetaxel IV infusion was administered at a starting dose of 75 mg/m\\^2 on Day 1 of Cycle 1 followed by 100 mg/m\\^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.\n\nAdjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 17.","id":"OG001","title":"Trastuzumab+Pertuzumab+Docetaxel"},{"description":"Neoadjuvant (Pre-Operative) Treatment: Participants received trastuzumab IV infusion at a loading dose of 8 mg/kg and pertuzumab IV infusion at a loading dose of 840 mg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 6 mg/kg trastuzumab and 420 mg pertuzumab on Day 1 of Cycles 2-4.\n\nAdjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by docetaxel 75 mg/m\\^2 IV on Day 1 of Cycle 5 followed by docetaxel 100 mg/m\\^2 for three cycles (Cycles 6-8) if no dose-limiting toxicity occurred. For Cycles 9 to 11, participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles. Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 12 until Cycle 17.","id":"OG002","title":"Trastuzumab+Pertuzumab"},{"description":"Neoadjuvant (Pre-Operative) Treatment: Participants received pertuzumab IV at a loading dose of 840 mg on Day 1 of Cycle 1 (21-day cycle) followed by a maintenance dose of 420 mg on Day 1 of Cycles 2-4. Docetaxel IV infusion was administered at a starting dose of 75 mg/m\\^2 on Day 1 of Cycle 1 followed by 100 mg/m\\^2 on Day 1 of Cycles 2-4, if no dose limiting toxicity occurred.\n\nAdjuvant (2-Week Post-Operative) Treatment: Participants received trastuzumab 6 mg/kg IV followed by FEC on Day 1 and every 3 weeks thereafter for three cycles (Cycles 5-7). Trastuzumab 6 mg/kg IV was continued every 3 weeks from Cycle 8 to Cycle 21.","id":"OG003","title":"Pertuzumab+Docetaxel"}],"paramType":"NUMBER","populationDescription":"ITT Population; Analysis was performed according to initial randomization. n = number of participants included in the specified hormone receptor status.","reportingStatus":"POSTED","timeFrame":"Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)","title":"Percentage of Participants Achieving pCR by Hormone Receptor Status","type":"PRIMARY","unitOfMeasure":"percentage of participants"}